Fenofibrate, a PPARα agonist, can inhibit the growth of gliomas [43], while NF-κB modulates tumor formation and progression by inducing the expression of oncogenes involved in proliferation, survival, angiogenesis, and metastasis [44]. Here, PPARA is linked to central nervous system cancer.